ICAGEN, INC.

Basic Information

4222 EMPEROR BLVD STE 350
DURHAM, NC, 27703-8030

Company Profile

n/a

Additional Details

Field Value
DUNS: 147452275
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 12


  1. IGF OT IGF SBIR PHASE I TOPIC SYSTEMIC TARGETED RADIONUCLIDE THERAPY FOR CANCER TREATMENT PERIOD OF PERFORMANCE

    Amount: $300,000.00

    Not Available

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. XRpro Radioactive Cesium Decorporation Agents

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Caldera aims to develop an inexpensive, stable, selective, decorporation (decorp) agent for cesium-137 (Cs-137). Cs-137 is easily obtainable by terrorists and trea ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. XRpro Radioactive Cesium Decorporation Agents

    Amount: $600,000.00

    DESCRIPTION provided by applicant Caldera aims to develop an inexpensive stable selective decorporation decorp agent for cesium Cs Cs is easily obtainable by terrorists and trea ...

    SBIR Phase I 2014 Department of Health and Human Services National Institutes of Health
  4. Selective Decorporation Agents for NIAID

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): This Phase II project continues the successful Phase I discovery of novel decorporation agents that are selective for radioactive strontium (Sr). This project cons ...

    SBIR Phase II 2011 Department of Health and Human Services
  5. Probes for Transient Kinase Complexes

    Amount: $98,917.00

    DESCRIPTION (provided by applicant): Most cellular processes are regulated by reversible protein phosphorylation, which is controlled by protein kinases and phosphatases. Caldera Pharmaceuticals and M ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. XRpro Technology for the Detection and Evaluation of Carcinogens

    Amount: $200,000.00

    DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. In Phase I, Caldera will demonstrate the feasibility of using its nove ...

    SBIR Phase I 2010 Department of Health and Human Services
  7. Iron Man: Novel Technologies for Autonomous Defense

    Amount: $100,000.00

    Caldera Pharmaceuticals proposes to develop a highly metal-selective system to maintain iron concentrations in the body at optimal levels to prevent infections. The system will control iron without th ...

    STTR Phase I 2009 Defense Advanced Research Projects Agency Department of Defense
  8. Innovative technologies to effectively treat multi-drug resistant and/or biofilm-embedded bacteria

    Amount: $100,000.00

    Antibiotic resistance is a major concern for both military and civilian populations. The US FDA reports that about 70 percent of bacteria that cause infections in hospitals are resistant to at least o ...

    STTR Phase I 2009 Defense Advanced Research Projects Agency Department of Defense
  9. XRpro Discovery of Decorporation Agents

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will use award-winning XRpro, a high throughput, label-free technology for producing nano-engineered radionuclide decorporation agents that ...

    SBIR Phase I 2009 Department of Health and Human Services
  10. Biomolecular Taggants for Covert Tracking and Watermarking

    Amount: $736,289.00

    Functional taggants are paints or inks that change their optical properties in response to specified environmental conditions, such as the presence of a chemical related to illicit weapon activities. ...

    SBIR Phase II 2009 Air Force Department of Defense

Agency Micro-sites

US Flag An Official Website of the United States Government